Endostar combined with concurrent chemoradiotherapy in treatment of local advanced non -small cell lung cancer in elderly patients

Abstract

Objective To investigate the short -term efficacy,safety and toxicities and tolerance of concurrent chemoradiotherapy combined with endostar for advanced non - small cell lung cancer (NSCLC) in elderly patients.Methods A total of 39 patients were randomly divided into trial group (19 cases) and control group(20 cases).In the trial group,the patients received endostar combined with chemoradiotherapy concurrently.In the control group,the patients received only chemoradiotherapy concurrently.The patients were given intensity - modulated radiotherapy ( IMRT),the dose of primary tumors and involved lymph nodes was 60 - 76 Gy/30 - 38 times for 6 - 8 weeks.Concurrently they were administrated chemotherapy with or without endostar.Docetaxel 60 mg/m2 on day 1,DDP 30 mg/m2 on day 1 -3,the chemotherapy was repeated every 21 days as a cycle.The endostar was given 15 mg/d from day 1 - 14 simultaneously.The efficacy was evaluated according to RECIST criteria,quality of life (QOL) was evaluated by karnofsky,safety was evaluated according to NCICTC 3.0 version criteria.Results The overall response rate was 84.2％ in the trial group and 50.0％ in the control group respectively ( P ＜ 0.05).The clinical benefit rate was 94.7％ in the trial group and 70.0％ in control group ( P ＜ 0.05).The rates of improved and stabled QoL were 94.7％ and 90.0％ ( P ＞ 0.05),respectively.The main side effects were marrow suppression and gastrointestinal symptoms.The total incidence of side effects in treatment group was higher than that in control group,but there was no significanct difference existed ( P ＞ 0.05).Conclusions Endostar combined with concurrent chemoradiotherapy is effective, safe and well -tolerable in the treatment of advanced NSCLC in elderly patients. Key words: Recombinant human endostatin(Endostar); Non- small cell lung cancer; Chemotherapy; Radiotherapy; Elderly